Clareo Health | Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations
Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Continuous health plan eligibility in the pre- and post-index periods
age ≥40 years at the index date
Presence of at least 1 claim with an ICD-9-CM code for COPD in any diagnosis field (490.xx, 491.xx, 492.xx, 496.xx) in the pre- and post-index period
≥1 exacerbation in the pre-index period (defined as a COPD-related Emergency Room visit or hospitalization)
≥1 prescription claim for ipratropium or ipratropium/albuterol combination in the pre-index period
an index event of at least one pharmacy claim for TIO (tiotropium) combination in the pre-index period during the study period (January 1, 2003 through April 30, 2008)
≥2 prescriptions for TIO (including the index prescription) during the post-index period
You may not be if
presence of comorbid conditions (respiratory cancer, cystic fibrosis, fibrosis due to tuberculosis \[TB\], and bronchiectasis, pneumonociosis, pulmonary fibrosis, pulmonary TB, sarcoidosis) during the pre- and post-index periods
use of FSC in pre-index period
exacerbation (emergency room visit or hospitalization) within 30 days after the index date
